What smart money is saying about ElectroCore
1 fund in our archive has pitched ElectroCore — most recently Rogue Funds in December 2024.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- Rogue FundsDecember 2024
ElectroCore is a high-growth, high-margin company expected to achieve profitability in the next six months, with significant long-term potential despite short-term challenges from warrant dilution and scaling issues.
Read the full thesis
Read every full thesis on ElectroCore
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→